How can we determine the role of radiotherapy in the treatment of localized aggressive non Hodgkin's lymphoma? by Bonnet, Christophe & Fillet, Georges
How Can We Determine the Role
of Radiotherapy in the Treatment
of Localized Aggressive Non-
Hodgkin’s Lymphoma?
TO THE EDITOR: In the recently published phase III trial by
Groupe d’Etude des Lymphomes de l’Adulte (GELA)—a group of
authors who are opponents of adjuvant radiotherapy in treatment of
aggressive localized non-Hodgkin’s lymphoma—the role of radio-
therapy was questioned again.1,2 However, we believe that there are
certain drawbacks in their trial. First, primary failures are two times
more common in the group assigned to adjuvant radiotherapy (6% v
3%), although the two groups were treated with the same chemother-
apy regimen (four cycles of cyclophosphamide, doxorubicin, vincris-
tine, and prednisone [CHOP]). Secondly, more than 10% of the
patients allocated to adjuvant radiotherapy did not receive it, and in
one fourth of patients, this was attributed to poor response obtained
with CHOP chemotherapy. Thus, the two groups, although they ap-
pear to be well-balanced with respect to stage, age-adjusted interna-
tional prognostic index scores, and other factors such as bulky disease,
do not seem similar with respect to treatment sensitivity. Another
drawback of the study that may have affected the results was the
administration of radiotherapy to the majority of the partial respond-
ers in the CHOP alone arm (six of eight patients). Despite all of these
factors negatively influencing the results of CHOP plus radiotherapy,
the total number of relapsed patients in this group was lower than the
total number of relapsed patients treated only with chemotherapy
(66 v 79 patients). More interestingly, although not mentioned in the
study, radiotherapy achieved its objective, as the infield failure rates
decreased more than half by radiotherapy when compared with the
group receiving only chemotherapy (21% v 47%).
Fewer lymphoma relapses (66 v 79 patients) despite higher
lymphoma-related deaths (70 v 65 patients) in the CHOP plus radio-
therapy arm seems paradoxical, and the authors claim that the admin-
istration of radiotherapy alters the pattern of localization of relapses,
but does not decrease the overall rate. In their reply3 to correspon-
dences concerning the GELA’s former trial, they state that the aim of
first-line treatment of localized lymphoma is to improve survival
rather than to control local disease. But how can we talk about cure
without controlling malignancy locally? In contrast to many other
malignant diseases, negative effect of local recurrence on survival in
lymphomas may be offset by the efficacy of salvage treatments. But still
the adverse effect of bulky disease on survival has been demonstrated
in a multivariate analysis.2
Another important point that must be mentioned, which was
also observed in this study, was the different sensitivity and outcome of
aggressive non-Hodgkin’s lymphomas to the same treatment. This
difference may depend on many and even unknown factors such as
WHO classification, site of origin of lymphoma, and pattern of gene
and protein expression, which may be different even in the same
lymphoma type.4
In order to prove the benefit of radiotherapy in localized aggres-
sive non-Hodgkin’s lymphomas, it would be better to stage patients
with positron emission tomography scanning rather than with con-
ventional imaging, and to include patients only with a single WHO-
classified disease entity with same localization, size, and International
prognostic index scores. In this way the groups can be made more
homogenous with respect to treatment sensitivity.
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IN REPLY: We thank Drs Gemici and Salepci for their interest in
our study.1 We are not opponents of adjuvant radiotherapy in aggres-
sive localized non-Hodgkin’s lymphoma. In our article, we analyzed
the mature data of a trial initiated in 1993 to compare radiotherapy
versus nothing after four cycles of chemotherapy.
According to the comments by Gemici and Salepci, primary
failures were twice as common in the group assigned to radiotherapy.
Indeed primary failures at the end of treatment were observed in 17
(6%) of 295 assessable patients assigned to the combined modality as
compared with nine (3%) of 273 patients assigned to cyclophospha-
mide, doxorubicin, vincristine, and prednisone (CHOP) alone. How-
ever, these values are not statistically significant (P .16).
As presented in Table 1, there is no significant difference in
relapse rate between the two arms. The death rate related to the
lymphoma is the same in both groups (24%). Gemici and Salepci are
right when they state that more than 10% of the patients allocated to
adjuvant radiotherapy did not receive it. As mentioned in Results
section of our article, 12 of 299 patients allocated to chemotherapy
could not be irradiated because of progression (according to the pro-
tocol) or death during CHOP induction and 23 could not receive
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radiation because of a medical decision by local investigators or refusal
of the patients. Such protocol deviations are inescapable in a trial
conducted on a multicenter basis and reflect real medical practice. In
our opinion, they legitimize the analysis performed on an intention-
to-treat basis. Because one might argue that such protocol deviations
might have influenced negatively the results of CHOP plus radiother-
apy, we performed an as-treated analysis for patients in complete
remission at the end of treatment. The as-treated analysis (not in-
cluded in our article) compares the outcomes of complete response
patients who have or have not received radiotherapy. No signifi-
cant difference is observed in terms of disease-free or overall sur-
vival rates (Table 1).
We agree with comments concerning the histologic and stage-
adapted International prognostic index heterogeneities of the in-
cluded cohorts. Analyses restricted to patients with DLBCL fail to
demonstrate any advantage of radiotherapy (Table 1). Similarly, anal-
yses restricted to patients with limited disease (excluding patients with
stage II bulky disease) do not affect our conclusions.
Finally, we know that the addition of anti-CD20 to CHOP im-
proves the results in term of complete response rate, event-free sur-
vival, and overall survival, particularly in a subset of elderly patients
with a low-risk age-adjusted International prognostic index score.2,3
In our study, we observed a 5-year overall survival of 72% after 4 cycles
of CHOP repeated at 21-day intervals (CHOP 21). By adding ritux-
imab, we hoped for an increase of approximately 15% in survival.3
Thus, taking into account the percentage of deaths related to natural
causes in this elderly population, the demonstration of a potential
benefit of radiotherapy will be even more difficult to assess in a study
including rituximab.
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Sunitinib Malate and Multiple
Receptor Tyrosine Kinases Inhibitors:
Are They Also Novel Drugs for
Chronic and Neurophatic Pain?
TO THE EDITOR: Recently, I read with interest the article
“Sunitinib: From Rational Design to Clinical Efficacy”1 published in
the March 1, 2007, issue of the Journal of Clinical Oncology. Interest-
ingly, Chow et al reported a range of in vitro and in vivo RTK (RTKs
are transmembrane proteins at the cell surface that transduce extra-
cellular signals to the cytoplasm, which may be inhibited by sunitinib)
targets that have been further validated by the clinical activity observed
in patients treated with sunitinib and other agents inhibiting these
pathways. “However,” they added, “the contribution and/or domi-
nance of inhibition of which specific RTK pathways are associated
with sunitinib-induced responses are not well understood and are
under active investigation.”1
The authors reported data on preclinic and clinic phase I, II,
and III trials. They correctly concluded that although initially
promising, RTK targets need additional validation in phase II/III
trials. Overall, they said, the clinical benchmarking of an agent that
influences multiple signaling pathways of tumor, stromal, and
endothelial compartments should stimulate additional research
into the biology of responsive tumors. Challenges ahead include
the ability to combine sunitinib with other therapies where toxic-
ities may be overlapping, optimization of dosing regimens, and
additional assessment and development of patient selection crite-
ria. Reading this interesting article, I recalled another recently
published article2 where the authors discussed how the past decade
has been characterized by a better understanding of physiology of
chronic pain. These other authors reported that nerve-growth
factor (NGF),2 “the founding member of the neurotrophin family
of structurally related secreted proteins, binds to two types of
receptors: a common receptor, p75NTR, which binds all neurotro-
phins with a similar affinity, and members of the trk family
of receptor tyrosine kinases (trkA, trkB, and trkC), which bind






PNo. % No. %
Intention to treat 277 299
Relapse 79 29 66 22 .07
Death due to lymphoma 65 24 70 24 .98
5-year EFS 61 64 .6
5-year OS 72 68 .5
As treated 255 259
5-year DFS 64 71 .2
5-year OS 75 75 .6
Restricted to DLBCL 187 223
5-year EFS 63 62 .7
5-year OS 74 67 .3
Restricted to patients with
limited-stage disease
248 270
5-year EFS 61 66 .3
5-year OS 70 72 .9
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and pred-
nisone; EFS, event-free survival; OS, overall survival; DLBCL, diffuse large
B-cell lymphoma; DFS, disease-free survival.
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